Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson’s Disease
Condition(s):Parkinson’s Disease (PD)Last Updated:September 6, 2023Active, not recruiting